Mr. Hugh Rogers reports

BIONXT SOLUTIONS INC. PROVIDES UPDATE ON PRIOR DEBENTURE

Prior to expiry, Bionxt Solutions Inc. has amended the terms of a previously issued unsecured convertible debenture in the principal amount of $2,808,000, bearing interest at a rate of 8 per cent per annum and previously maturing on Dec. 7, 2024. The maturity date of the debenture was extended one year to Dec. 7, 2025, and the company is now entitled, from time to time, to issue common shares in the capital of the company at a price of 28.5 cents per interest share, being the market price at the time of amendment, in satisfaction of accrued and unpaid interest. For further details regarding the debenture, see the company's news release dated Dec. 7, 2022, a copy of which is available under the company's profile at SEDAR+.

Pursuant to the terms of the amended debenture, the company issued 1,459,649 interest shares in satisfaction of $416,000 in accrued and unpaid interest. Such interest shares are subject to a hold period expiring May 9, 2025.

About Bionxt Solutions Inc.

Bionxt is a bioscience accelerator focused on next-generation drug formulations and delivery systems, diagnostic screening tests, and new active pharmaceutical production and evaluation, including: precision transdermal and oral dissolvable drug formulations; rapid, low-cost infectious disease and oral health screening tests; and standardization and clinical evaluation of emerging active pharmaceutical ingredients for neurological applications. The company has research and development operations in North America and Europe, with an operational focus in Germany, and is currently focused on regulatory approval and commercialization of medical products for European markets.

We seek Safe Harbor.